Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Theriva BiologicsFRA:SFY0 23 EV-to-FCF is -0.24 as of Aug. 25, 2026. GuruFocus rates FRA:SFY0 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 321 Biotechnology companies, Theriva Biologics ranks worse than 311526.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Theriva Biologics's Enterprise Value is €2.57 Mil.
Theriva Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-10.94 Mil. Therefore, Theriva Biologics's EV-to-FCF for today is -0.24.
The historical rank and industry rank for Theriva Biologics's EV-to-FCF or its related term are showing as below:
FRA:SFY0'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.37 Med: -0.17 Max: 0.09
Current: -0.24
During the past 13 years, the highest EV-to-FCF of Theriva Biologics was 0.09. The lowest was -0.37. And the median was -0.17.
FRA:SFY0's EV-to-FCF is ranked worse than 100% of 321
companies
in the Biotechnology industry
Industry Median: 18.66
vs FRA:SFY0: -0.24
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Theriva Biologics's PE Ratio (TTM) for today is calculated as:
Theriva Biologics's share price for today is €2.42.
Theriva Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.571.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Theriva Biologics EV-to-FCF Related Terms
Theriva Biologics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Theriva Biologics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:SFY0 vs BIVI, BCLI, LNAI: EV-to-FCF Comparison
For the Biotechnology subindustry, Theriva Biologics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theriva Biologics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theriva Biologics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Theriva Biologics's EV-to-FCF falls into.
Theriva Biologics's current Enterprise Value is €2.57 Mil.
Theriva Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theriva Biologics (FRA:SFY0) has a EV-to-FCF of -0.24 as of Aug. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Theriva Biologics and its competitors. According to the industry distribution chart, Theriva Biologics ranks #999999 out of 321 companies in the Biotechnology industry.
Is Theriva Biologics' EV-to-FCF too high?
Theriva Biologics' current EV-to-FCF is -0.24. Based on the distribution chart, Theriva Biologics ranks #999999 out of 321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Theriva Biologics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' EV-to-FCF compare to BIVI and BCLI?
According to the Biotechnology industry distribution chart, Theriva Biologics ranks #999999 out of 321 companies for EV-to-FCF. This places Theriva Biologics in the lower half of its industry. The industry median EV-to-FCF is 18.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 18.66, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Theriva Biologics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 18.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theriva Biologics's current EV-to-FCF is -0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (FRA:SFY0) has a current EV-to-FCF of -0.24. The current EV-to-FCF is -0.24. Theriva Biologics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Theriva Biologics (FRA:SFY0), the current EV-to-FCF is -0.24 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
23GF Score
Get the complete analysis for FRA:SFY0
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SFY0 has been successfully added to your 
